Summary of Medical Aesthetic Industry Conference Call Industry Overview - The medical aesthetic industry is experiencing a slowdown in growth, with leading chain institutions and light medical aesthetic models still maintaining growth. Single stores or non-compliant institutions are facing difficulties, and the proportion of channel medical aesthetics is decreasing [1][2][12]. Key Insights and Arguments - Revenue growth for institutions is up 6% year-on-year, with increased customer flow but a decrease in average transaction value (ATV) by approximately 6%. First-tier cities performed particularly well, with an expected annual growth rate of about 10% for chain institutions [1][2][3][4]. - Promotional activities were advanced to September, significantly boosting revenue, with the repurchase rate of existing customers rising to 61% [1][5]. - The pricing strategy varies significantly among products, with low-priced products used for customer acquisition and high-priced products maintaining profit margins. Institutions attract new customers with low initial prices, then revert to original prices for subsequent treatments [1][9][10]. - Regulatory tightening has led to reduced advertising expenditures in traditional channels, shifting focus to customer referrals and internal membership management systems, resulting in decreased marketing costs but improved ROI [1][11]. Market Dynamics - The industry is expected to focus more on profit margins rather than solely on revenue growth, with a projected overall revenue growth of less than 10% by 2026 and a potential further decline in ATV [3][25]. - The customer demographic has shifted, with a 16% year-on-year increase in customer flow in September, and a notable rise in the proportion of returning customers [5]. - High-end products like collagen and hyaluronic acid are expected to see increased procurement, while non-compliant products will be suspended [3][25]. Product Performance - Different price segments are performing well, with significant growth in customer acquisition products such as water light needles and photon rejuvenation [6][8]. - The price of some products has decreased, such as the Ningbo Weimei 4mg product, while high-end products have maintained stable pricing [8][9]. - The market for botulinum toxin has shown stable growth, with annual growth rates exceeding 10% from 2023 to 2025, despite strict regulations limiting advertising [24]. Future Trends - The industry is expected to develop more healthily and sustainably, with a focus on compliance and quality. Non-compliant small institutions may be eliminated due to increased regulatory scrutiny [12][13]. - Mergers and acquisitions are occurring, particularly among traditional institutions that have not adapted to the light medical aesthetic trend [14]. - Institutions prefer self-built stores over acquiring local existing institutions to maintain brand consistency and leverage operational advantages [15]. Conclusion - The medical aesthetic industry is navigating a complex landscape of regulatory changes, shifting consumer preferences, and competitive pressures. Institutions are adapting by refining their marketing strategies, focusing on customer retention, and optimizing product offerings to ensure sustainable growth in a challenging environment [12][30].

Summary of Langzi Co., Ltd. Conference Call Company Overview - **Company**: Langzi Co., Ltd. - **Industry**: Medical Aesthetics and Fashion Retail Key Financial Performance - **Net Profit**: For the first three quarters of 2025, the net profit attributable to shareholders reached 989 million yuan, a year-on-year increase of 366% [2][3] - **Non-recurring Net Profit**: Decreased by 4.1% year-on-year, indicating a need for improvement in profit quality [2][3] - **Operating Cash Flow**: Slight decline observed, reflecting potential operational challenges [2][3] Medical Aesthetics Business - **Revenue Contribution**: Medical aesthetics revenue exceeded 50% of total revenue for the first time, reaching 2.237 billion yuan, a 2.5% increase year-on-year [2][4] - **Gross Margin**: Improved to 55.6%, up 1.8 percentage points year-on-year [2][4] - **Net Profit Contribution**: Decreased by 33.5% year-on-year, indicating challenges in profitability [2][4] - **Revenue Breakdown**: - Milan Fabric Division: 1.159 billion yuan, up 2.2% - Financial Services Division: 393 million yuan, up 9.7% - Hancheng Division: 318 million yuan, up 16% - Wuhan Wuzhou: 146 million yuan, down 9% - Changsha Yamei: 132 million yuan, down 13% - Gao Doctor: 109 million yuan, down 11% [4] Women's Clothing Business - **Revenue**: Approximately 1.407 billion yuan, stable year-on-year [5] - **Gross Margin**: Maintained at around 64% [5] - **Net Profit Contribution**: Increased by 1% year-on-year [5] - **Online Sales Growth**: Significant growth of over 22%, accounting for more than 46% of total women's clothing revenue [5] - **Inventory**: Total inventory at the end of Q3 was approximately 769 million yuan, with a focus on preparing for Q4 [5] Yingdong Division Performance - **Revenue**: Approximately 674 million yuan, a slight decline of 1.6% year-on-year [7] - **Gross Margin**: Decreased by 4.2 percentage points to 61.4% [7][8] - **Net Profit**: Approximately 6.87 million yuan, down 33% [8] Trends in Medical Aesthetics - **Revenue Trends**: Despite a 6% decline in half-year revenue, Q3 showed slight growth of about 2% [9] - **Product Mix Changes**: - Regenerative materials accounted for 22% of revenue, up 5.1 percentage points - Hyaluronic acid decreased to 12.6%, down 1.9 percentage points [9] - **Light Medical Aesthetics**: Increased focus on light medical aesthetics projects, with significant growth in revenue [10] Strategic Considerations - **Pricing Strategy**: Emphasis on providing comprehensive solutions rather than relying solely on product pricing [12] - **Cost Management**: Efforts to reduce customer acquisition costs through channel optimization and content marketing [12] - **M&A Strategy**: Active pursuit of high-quality medical aesthetics targets through external fund acquisitions, with a focus on integration [14][17] Market Environment and Future Outlook - **Market Conditions**: Current market conditions have influenced M&A activities, with many small institutions being acquired for better growth opportunities [15][16] - **Investment Plans**: Positive outlook on future growth, especially in new regions, with ongoing monitoring of potential targets [17] Cost and Supplier Dynamics - **Material Costs**: Decreased by 1.4 percentage points year-on-year, benefiting from strong supplier relationships [19] - **Supplier Power**: Upstream suppliers maintain significant power, particularly in high-end products [20] This summary encapsulates the key points from the conference call, highlighting the financial performance, business segments, strategic initiatives, and market dynamics of Langzi Co., Ltd.

Core Viewpoint - *ST Suwu is facing significant challenges, including a sharp decline in revenue and net profit, alongside ongoing arbitration regarding the exclusive agency rights for the AestheFill product, which is critical to its business operations [2][5][6]. Financial Performance - In Q3 2025, *ST Suwu reported a revenue decline of 63.93% year-on-year, amounting to 148 million yuan, with a net profit attributable to shareholders of approximately -43 million yuan, a drastic decrease of 308.72% compared to the previous year [2][4]. - For the first three quarters of the year, the company's revenue fell by 38.85% to 784 million yuan, and the net profit decreased by 294.03% to -87.47 million yuan, primarily due to significant impairment provisions for trade receivables [5][6]. Business Segments - The pharmaceutical business generated a total revenue of 468 million yuan, down 55.79% year-on-year, while the aesthetic biomedical segment achieved a revenue of 304 million yuan, reflecting a growth of 52.78% [5][6]. - The AestheFill product, crucial for the aesthetic segment, faced sales disruptions due to an ongoing arbitration case, which has created uncertainty for the company's future performance in this area [6][7]. Regulatory and Legal Issues - *ST Suwu is under scrutiny from the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure, leading to a formal investigation and potential penalties [7][9]. - The company has been implicated in inflating revenue figures by approximately 1.771 billion yuan from 2020 to 2023, raising concerns about its financial integrity and leading to multiple delisting risks [8][9]. Management Changes - Recent changes in the company's management include the resignation of the securities affairs representative, with a new appointment made to assist the board in fulfilling its responsibilities [9].

Core Viewpoint - *ST Suwu is facing significant challenges, including a sharp decline in revenue and net profit, alongside multiple delisting risks, particularly related to the arbitration case concerning the exclusive agency rights for the AestheFill product. Financial Performance - In Q3 2025, *ST Suwu reported a revenue decline of 63.93% year-on-year to 148 million yuan, with a net profit attributable to shareholders of approximately -43.05 million yuan, a drastic decrease of 308.72% compared to the same period last year [1][3] - For the first three quarters, the company's revenue fell by 38.85% to 784 million yuan, and the net profit decreased by 294.03% to -87.47 million yuan, primarily due to significant impairment provisions for trade receivables [4][5] - The pharmaceutical business generated a total revenue of 468 million yuan, down 55.79% year-on-year, while the medical aesthetics sector achieved a revenue of 304 million yuan, up 52.78% [4] Business Operations - The decline in revenue is attributed to a significant drop in income from pharmaceutical and medical aesthetics businesses, with the company admitting it is currently unable to continue selling AestheFill products due to ongoing arbitration [1][5] - AestheFill, a key product for *ST Suwu, was launched in 2024 and contributed significantly to the company's revenue, accounting for 35.55% of total revenue in Q1 2024 [5][6] Legal and Regulatory Issues - *ST Suwu is under scrutiny for alleged information disclosure violations, having received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation [7] - The company has been found to have inflated revenue by approximately 1.771 billion yuan from 2020 to 2023 through non-commercial trade activities, leading to multiple delisting risks [8][9] - The company has faced a series of legal challenges, including a criminal case against its subsidiary for tax fraud, which further complicates its financial situation [9]

Core Viewpoint - The company is currently awaiting approval for its botulinum toxin project, with the timeline for registration and results dependent on the National Medical Products Administration's review process [2]. Group 1: Project Status - The botulinum toxin project is in the queue for review and approval [2]. - The company confirms that its ongoing research projects are progressing normally [2]. Group 2: Financial Performance - The company reported a 40% decline in profits for the third quarter [2]. - There are inquiries regarding the progress of new product development and the potential for reversing the profit decline [2].

Core Viewpoint - The performance of the new consumption sector shows significant divergence, with companies like Pop Mart achieving impressive growth, while the capital market does not seem to respond positively, leading to a stark contrast between "performance growth and valuation adjustment" [1] Group 1: IP Economy Performance - Pop Mart's Q3 2025 financial report shows a substantial revenue increase of 245%-250% year-on-year, continuing its high growth trend from the first half of the year [3] - In the Chinese market, Q3 revenue grew by 185%-190%, with online channels surging by 300%-305% and offline channels increasing by 130%-135% [3] - The overseas market saw even more remarkable growth, with overall revenue up by 365%-370%, and the Americas market skyrocketing by 1265%-1270% [3] - Light Media, a leading company in the IP economy, reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% rise in net profit to 2.336 billion yuan for the first three quarters [4] - Despite these impressive results, companies like Pop Mart and Light Media experienced notable stock price adjustments, indicating that the market is more focused on sustainable growth potential and the ability to localize operations in overseas markets [4] Group 2: Pet Economy Growth - The pet economy has been a favored sector in the capital market, with companies like Zhongchong Co. and Guai Bao Pet seeing stock price increases until recently, when performance growth began to slow [6] - Zhongchong Co. reported a revenue of 3.860 billion yuan for the first three quarters, a year-on-year increase of 21.05%, and a net profit of 333 million yuan, up 18.21% [7] - Guai Bao Pet achieved a revenue of 4.737 billion yuan, a 29.03% increase, and a net profit of 513 million yuan, up 9.05% [8] - The pet market in China is still in its early stages compared to developed countries, with significant opportunities for growth as consumer demand diversifies [8][9] Group 3: Beauty Economy Decline - Companies in the beauty economy, such as Aimeike, Huaxi Biological, and Beitaini, are facing dual challenges of declining performance and valuation adjustments [10] - Aimeike's Q3 report shows a revenue of 1.865 billion yuan, down 21.49%, and a net profit of 1.093 billion yuan, down 31.05% [12] - Huaxi Biological reported a total revenue of 3.163 billion yuan, a decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% [13] - Beitaini's revenue for the first three quarters was 3.464 billion yuan, down 13.78%, with a net profit of 272 million yuan, down 34.45% [14] - The medical beauty industry is experiencing a strategic transformation, with a focus on high-end markets and product innovation, which may provide growth opportunities in the future [15]

Core Viewpoint - Aimeike, known as the "Maotai of the medical beauty industry," has reported disappointing financial results, with significant declines in both revenue and net profit for Q3 2025, raising concerns about its growth prospects and market position [2][5][8]. Financial Performance - In Q3 2025, Aimeike's revenue was 565 million, a year-on-year decline of 21.27%, and net profit was 304 million, down 34.61%. For the first three quarters of 2025, revenue totaled 1.865 billion, a decrease of 21.49%, with net profit at 1.09 billion, down 31.05% [2][8]. - The company's stock price fell to 157.05 yuan per share on the day of the report, a drop of 3.97%, and has since decreased by 73% from its peak market value of 180 billion in 2021, now valued at approximately 48.5 billion [2][5]. Product Performance - Aimeike's core products, "Haitai" and "Ruhua Tianzi," have seen significant revenue declines. For the first half of 2025, "Haitai" generated 744 million, down 23.79%, while "Ruhua Tianzi" brought in 493 million, down 23.99% [8][9]. - Despite maintaining high gross margins above 90%, the revenue drop and slight margin decline indicate growing concerns about the company's revenue structure and overall growth momentum [9][10]. Competitive Landscape - Aimeike's market dominance is being challenged as competitors like Huaxi Biological have introduced similar products, eroding the unique advantages previously held by "Haitai" [11][13]. - The emergence of alternative technologies, such as recombinant collagen, poses a threat to Aimeike's core offerings, further pressuring its performance [13]. Strategic Moves - Aimeike's acquisition of REGEN aims to enhance its product portfolio and international market access, but it has led to a significant increase in goodwill from 278 million to 1.65 billion, a rise of 493.44% [14][15]. - The company is currently embroiled in a legal dispute with its former distributor, which could impact the integration of REGEN and future revenue streams [15]. Conclusion - Aimeike is at a critical juncture, facing declining performance from its flagship products while struggling to establish new growth drivers amidst increasing competition and technological advancements [15].

Core Viewpoint - Aimeike, known as "the Moutai for women," is experiencing a significant decline in its business performance, with both revenue and net profit dropping sharply in recent quarters [1][5][10]. Financial Performance - In the first three quarters of 2025, Aimeike reported revenue exceeding 1.86 billion yuan, a year-on-year decrease of over 21%, and a net profit of nearly 1.1 billion yuan, down over 30% [1][5]. - This marks the first time in nearly a decade that Aimeike has experienced a decline in both revenue and net profit over three quarters [2][8]. - The company has seen a continuous decline in performance for four consecutive quarters, with no signs of recovery [2][8]. Product Performance - Aimeike's core products have lost market share, with revenue from its two main products declining in the first half of 2025 [3][11]. - The acquisition of the "童颜针" (Youth Needle) for nearly 1.4 billion yuan has not yet shown positive results in the company's financials [3][12]. - The revenue contribution from Aimeike's main products, including "嗨体" and "濡白天使," has decreased significantly, dropping from 98.57% in 2023 to 95.24% in the first half of 2025 [11][12]. Market Competition - The medical aesthetics industry is facing intensified competition, leading to squeezed profit margins for Aimeike [10][11]. - The market is shifting from expansion to value reconstruction, with a notable increase in competition from new entrants and evolving consumer demands [10][11]. - Aimeike's main products, which include gel and solution injection products, are facing challenges from competitors like 华熙生物 and 圣博玛, which have introduced similar products to the market [11][12]. Historical Context - Aimeike's revenue and net profit had been growing rapidly from 2016 to 2023, with revenue increasing from 141 million yuan to 2.87 billion yuan and net profit from 53 million yuan to 1.86 billion yuan during the same period [5][6]. - The company experienced a slowdown in growth starting in 2024, with revenue and net profit growth rates falling to single digits for the first time since 2016 [6][10].

Industry Overview - In 2025, social consumption and retail enterprises are slowly recovering, with segments like gold jewelry benefiting from high gold prices, while cosmetics and medical aesthetics face intense competition and the rise of domestic brands. Notably, "emotional consumption" remains a key indicator of market vitality [2][8]. Segment Analysis Gold Jewelry - The industry has undergone significant changes, with high gold prices and declining wedding demand affecting traditional brand competitiveness. The rise of emotional consumption and social media marketing has led to the emergence of new brands with differentiated products and consumer insights. Opportunities are seen in high-end Chinese gold and trendy gold segments [3][25]. Retail E-commerce - Offline retailers are transforming from selling "goods" to offering "services and experiences," leveraging their advantages to attract traffic back. Online cross-border e-commerce is expected to enter a demand improvement phase with the easing of interest rates, further enhanced by AI integration [3][19]. Cosmetics - Domestic brands are capitalizing on cultural roots and emotional value to increase market share. Innovations in product safety and emotional value are key, with opportunities in regional and technological narratives, sensitive skin anti-aging, and domestic color cosmetics [3][85]. Medical Aesthetics - High-end consumers show resilience, with a focus on differentiated products from upstream manufacturers and mergers and acquisitions among downstream medical institutions to drive growth [3][5]. Investment Recommendations - Gold Jewelry: Favor brands with differentiated product strength and consumer insights, recommending Chao Hong Ji, Lao Pu Gold, and Chow Tai Fook, with beneficiaries including Chow Sang Sang [3][52]. - Retail E-commerce: Support offline retailers adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket, Ai Ying Shi, Ji Hong Co., and Sai Wei Times [3][82]. - Cosmetics: Highlight domestic brands that meet emotional value and safety innovation, recommending Mao Ge Ping, Pechoin, Shangmei Co., Juzi Biological, Wanmei Biological, and Runben Co. [3][52]. - Medical Aesthetics: Focus on differentiated medical aesthetic product manufacturers and expanding chain medical institutions, recommending Ai Mei Ke and Ke Di-B, with beneficiaries including Mei Li Tian Yuan Medical Health [3][52].

Core Insights - The company reported a decline in revenue and net profit for Q3 2025, with revenue at 566 million and a year-on-year decrease of 21.27% [1] - The company is actively expanding its product pipeline and international market presence, with several new products approved for launch [2] - Despite short-term business pressures, the company maintains a leading gross margin and market share, with projected net profit growth in the coming years [3] Financial Performance - In Q3 2025, the company achieved a net profit of 304 million, down 34.61% year-on-year, and a non-recurring net profit of 255 million, down 42.37% [1] - The sales expense ratio increased by 6.38 percentage points year-on-year, while gross and net profit margins faced slight pressure [1] - R&D expenses as a percentage of revenue rose to 14.30% in Q3 2025, reflecting a commitment to innovation [1] Product Development - The company launched a new product, "Gekela," for treating chin retrusion in May 2025, and received approval for minoxidil solutions in September 2025 [2] - Several products are in the pipeline, including an A-type botulinum toxin for wrinkle treatment and semaglutide injections for weight management [2] - The acquisition of 85% of REGEN Biotech, Inc. enhances the company's product offerings and supports its international expansion strategy [2] Market Outlook - The company anticipates net profits of 1.33 billion, 1.54 billion, and 1.72 billion for 2025-2027, with year-on-year growth rates of -32.2%, +16.3%, and +11.7% respectively [3] - Current stock price corresponds to a PE ratio of 37X for 2025, 31X for 2026, and 28X for 2027, indicating potential for investment [3]